EUCTR2014-002014-22-HU进行中（未招募）不适用
An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer
Országos Onkológiai Intézet0 个研究点开始时间: 2014年5月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histological proven ovarian cancer
- •Advanced cancer
- •Appropriate laboratory functions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Clinical trial of oral L-Arginine therapy for the patients with HAM/TSPHTLV-1-associated myelopathy/Tropical spastic paraparesisD015493JPRN-jRCTs071180068TAKASHIMA HIROSHI20
进行中（未招募）
不适用
Continuation of cholic acid treatment for people with bile acid disorders who have previously taken part in clinical trials of cholic acid capsules.Patients with inborn errors of bile acid synthesis and metabolismMedDRA version: 14.0Level: PTClassification code 10070882Term: Inborn error in primary bile acid synthesisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004528-36-Outside-EU/EEAAsklepion Pharmaceuticals, LLC30
已完成
不适用
Single center, open label, non-randomized, non-placebo controlled study to investigate the pharmacokinetics, metabolic disposition, and mass balance after single administration of 20 mg [14C]neladenoson bialanate (oral solution) in healthy male subjects.10019280heart failureNL-OMON44620Bayer AG6
进行中（未招募）
1 期
A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of MLD patients with high residual level of voluntary functioEUCTR2007-007165-20-DKShire Pharmaceuticals Ireland Limited6
进行中（未招募）
不适用
A single center, open-label, non-randomized, uncontrolled, multiple-dose, dose escalation study of the safety, pharmacokinetics and efficacy of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of patients with late infantile metachromatic leukodystrophy (MLD)ate infantile metachromatic leukodystrophy (MLD)MedDRA version: 9.1Level: LLTClassification code 10024381Term: LeukodystrophyEUCTR2006-005341-11-DKShire Pharmaceuticals Ireland Limited12